Clinical Trial Update: Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a triple combination of gecacitinib, donafenib, and a PD-1 inhibitor as an immune rechallenge therapy for unresectable hepatoc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib (donafenib)
• Gecacitinib (Gecacitinib)
• PD-1 inhibitor

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING